Home > Insider Trading > Filing (0001549595-24-000122)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1549595	Nurix Therapeutics Inc.	NRIX	Pharmaceutical Preparations (2834)	270838048

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1817199	Christine Ring	C/O Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco CA 94158	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-10-01	5,760	$1.86	30,352	No	4	M	Direct
Common Stock	Disposition	2024-10-01	5,460	$22.19	24,892	No	4	S	Direct
Common Stock	Disposition	2024-10-01	300	$22.81	24,592	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2024-10-01	5,760	$0.00	5,760	$1.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
71,266		2029-09-30	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Represents the weighted average sale price. The lowest price at which shares were sold was $21.75 and the highest price at which shares were sold was $22.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Represents the weighted average sale price. The lowest price at which shares were sold was $22.76 and the highest price at which shares were sold was $22.85. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.